As ARID1A is frequently mutated in various types of human cancer—including ovarian, gastric, pancreatic, and colorectal cancers25–27—and its mutations result predominantly in loss of function, our study may have important translational implications through it suggesting KLF5 as a potential therapeutic target for ARID1A-deficient cancers. This evidence concerns the gene KLF5 and cancer.